Patents by Inventor Steven Gregory Mischke

Steven Gregory Mischke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antiproliferative benzo [B] azepin-2-ones
    Patent number: 9611224
    Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3 and R4 are described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 4, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Xiaochun Han, Yan Lou, Christophe Michoud, Steven Gregory Mischke, Stacy Remiszewski, Kenneth Carey Rupert
  • Azaheterocycles as BIR2 and/or BIR3 inhibitors
    Patent number: 9422332
    Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, m, n and q are described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: August 23, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joan Heather Hogg, Kang Le, Yan Lou, Steven Gregory Mischke, Stacy Remiszewski
  • Dimeric compounds
    Patent number: 9409888
    Abstract: Disclosed are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein Z, X, Q and R1 are as described in this application, and methods of using the compounds in the treatment of cancer.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: August 9, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Steven Gregory Mischke
  • DIMERIC COMPOUNDS
    Publication number: 20160024055
    Abstract: Disclosed are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein Z, X, Q and R1 are as described in this application, and methods of using the compounds in the treatment of cancer.
    Type: Application
    Filed: December 9, 2013
    Publication date: January 28, 2016
    Inventor: Steven Gregory Mischke
  • ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES
    Publication number: 20150353499
    Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3 and R4 are described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Application
    Filed: July 11, 2013
    Publication date: December 10, 2015
    Applicant: Hoffman-La Roche Inc.
    Inventors: Xiaochun Han, Yan Lou, Christophe Michoud, Steven Gregory Mischke, Stacy Remiszewski, Kenneth Carey Rupert
  • AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS
    Publication number: 20150210739
    Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, m, n and q are described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Application
    Filed: August 6, 2013
    Publication date: July 30, 2015
    Inventors: Joan Heather Hogg, Kang Le, Yan Lou, Steven Gregory Mischke, Stacy Remiszewski
  • Thiazolyl-benzimidazoles
    Patent number: 8044213
    Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: October 25, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jianping Cai, Shaoqing Chen, Yi Chen, Xin-Jie Chu, Robert Alan Goodnow, Jr., Kang Le, Kin-Chun Luk, Steven Gregory Mischke, Peter Michael Wovkulich
  • Halo-substituted pyrimidodiazepines
    Patent number: 8003785
    Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: August 23, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jianping Cai, Shaoqing Chen, Xin-Jie Chu, Kin-Chun Luk, Steven Gregory Mischke, Hongmao Sun, Peter Michael Wovkulich
  • MCH receptor antagonists
    Patent number: 7803816
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: September 28, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Shawn David Erickson, Nader Fotouhi, Robert Francis Kester, Kyungjin Kim, Steven Gregory Mischke, Yimin Qian, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley, Hong Wang
  • Thiazolyl-Benzimidazoles
    Publication number: 20100160308
    Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.
    Type: Application
    Filed: December 10, 2009
    Publication date: June 24, 2010
    Inventors: Jianping Cai, Shaoqing Chen, Yi Chen, Xin-Jie Chu, Robert Alan Goodnow, JR., Kang Le, Kin-Chun Luk, Steven Gregory Mischke, Peter Michael Wovkulich
  • HALO-SUBSTITUTED PYRIMIDODIAZEPINES
    Publication number: 20090318408
    Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.
    Type: Application
    Filed: June 16, 2009
    Publication date: December 24, 2009
    Inventors: Jianping Cai, Shaoqing Chen, Xin-Jie Chu, Kin-Chun Luk, Steven Gregory Mischke, Hongmao Sun, Peter Michael Wovkulich
  • Substituted hydantoins
    Patent number: 7612212
    Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: November 3, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, Steven Gregory Mischke, John Anthony Moliterni, Hong Wang, Zhuming Zhang
  • Substituted hydantoins
    Publication number: 20070197617
    Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
    Type: Application
    Filed: January 25, 2007
    Publication date: August 23, 2007
    Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, Steven Gregory Mischke, John Anthony Moliterni, Hong Wang, Zhuming Zhang
  • 5-substituted-six-membered heteroaromatic glucokinase activators
    Patent number: 7132425
    Abstract: The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: November 7, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Wendy Lea Corbett, Kevin Richard Guertin, Nancy-Ellen Haynes, Robert Francis Kester, Francis A. Mennona, Steven Gregory Mischke, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar
  • Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
    Patent number: 7067529
    Abstract: Compounds of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: June 27, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Robert Bolin, Shoaqing Chen, Steven Gregory Mischke, Yimin Qian
  • Substituted piperidines
    Patent number: 7060713
    Abstract: The present invention provides compounds having formula (II): wherein X, n, R1–R12 are defined herein, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by formula (II) and a pharmaceutically acceptable carrier or excipient. The invention further provides a method for treating cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound represented by formula (II).
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: June 13, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kyungjin Kim, Emily Aijun Liu, Steven Gregory Mischke
  • Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
    Patent number: 7037924
    Abstract: Compounds of formula (I) are provided, wherein R1 and R2 are as designated in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: May 2, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Robert Bolin, Shaoqing Chen, Steven Gregory Mischke, Yimin Qian
  • Substituted piperidines
    Patent number: 6916833
    Abstract: The present invention provides compounds having formula (I): and formula (II): wherein X, n, and R1-R12 are defined herein, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by formula (I) or (II) and a pharmaceutically acceptable carrier or excipient. The invention further provides a method for treating cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound represented by formula (I) or (II).
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: July 12, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kyungjin Kim, Emily Aijun Liu, Steven Gregory Mischke
  • Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
    Publication number: 20040259910
    Abstract: Compounds of formula I are provided 1
    Type: Application
    Filed: April 19, 2004
    Publication date: December 23, 2004
    Inventors: David Robert Bolin, Shoqing Chen, Steven Gregory Mischke, Yimin Qian
  • Substituted piperidines
    Publication number: 20040180929
    Abstract: The present invention provides compounds having formula (I): 1
    Type: Application
    Filed: March 4, 2004
    Publication date: September 16, 2004
    Inventors: Kyungjin Kim, Emily Aijun Liu, Steven Gregory Mischke